Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Inclusion Criteria: * Diagnosis of acute myeloid leukemia (AML) according to WHO classification * At least 5% blasts in the bone marrow * With or without extramedullary disease * To be eligible for the dose-finding phase (closed as of 10/10) : * Relapsed patients must meet the following criteria: * Must have had a prior diagnosis of AML, but may NOT have inv(16) or t(8;21) cytogenetics * May be in first or any subsequent relapse * If in first relapse, remission duration must be less than one year * Refractory patients must meet the following criteria: * Must have had a prior diagnosis of AML * May have received one or more attempt at remission induction * Patients with treatment-related AML may be previously treated or untreated for secondary AML * To be eligible for the efficacy phase: * Relapsed patients must meet the following criteria: * Must have had a prior diagnosis of AML, with no restriction on prior cytogenetics * Must be in first relapse * Must not have received prior reinduction therapy * Refractory patients must meet the following criteria: * Must have had a prior diagnosis of AML * Must not have received more than one attempt at remission induction (which may consist of up to two therapy courses) * Patients with treatment-related AML must be previously untreated for secondary AML * No juvenile myelomonocytic leukemia or acute promyelocytic leukemia (APL; FAB M3) * Patients with the following CNS sta…